BCX logo

Bioceltix S.A. Stock Price

WSE:BCX Community·zł486.8m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 3 Fair Values set on narratives written by author

BCX Share Price Performance

zł88.00
-26.00 (-22.81%)
zł88.00
-26.00 (-22.81%)
Price zł88.00

BCX Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet with limited growth.

2 Risks
1 Reward

Bioceltix S.A. Key Details

zł0

Revenue

zł2.6m

Cost of Revenue

-zł2.6m

Gross Profit

zł14.4m

Other Expenses

-zł17.0m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Sep 23, 2026
-3.08
0%
0%
0%
View Full Analysis

About BCX

Founded
2016
Employees
43
CEO
Lukasz Bzdzion
WebsiteView website
bioceltix.com

Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. The company’s products include BCX-CM-J, a stem-cell based biological drug for the treatment of osteoarthritis in dogs; BCX-CM-AD, a drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses. The company was founded in 2016 and is headquartered in Wroclaw, Poland.

Recent BCX News & Updates

Recent updates

No updates